Editorial Board — Medscape Oncology
Board Members
- Harold J. Burstein, MD, PhD
- Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
- Harvard Medical School
- Bruce D. Cheson, MD
- Georgetown University
Georgetown University Hospital
Washington, DC
- Georgetown University
- David J. Kerr, MD
- University of Oxford
Oxford Cancer Centre
Oxford, United Kingdom
- University of Oxford
- Mark G. Kris, MD
- Memorial Sloan-Kettering Cancer Center
Weill Cornell Medical College
New York, New York
- Memorial Sloan-Kettering Cancer Center
- Corey J. Langer, MD
- University of Pennsylvania Medical School
Abramson Cancer Center
Philadelphia, Pennsylvania
- University of Pennsylvania Medical School
- Maurie Markman, MD
- Drexel University College of Medicine
Cancer Treatment Centers of America
Philadelphia, Pennsylvania
- Drexel University College of Medicine
- John L. Marshall, MD
- Georgetown University
Washington, DC
- Georgetown University
- Kathy D. Miller, MD
- Indiana University School of Medicine
Indiana University Simon Cancer Center
Indianapolis, Indiana
- Indiana University School of Medicine
- Richard M. Stone, MD
- Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
- Harvard Medical School
- Nicholas J. Vogelzang, MD
- University of Nevada School of Medicine
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
- University of Nevada School of Medicine
- Louis M. Weiner, MD
- Georgetown University Medical Center
Lombardi Comprehensive Cancer Center
Washington, DC
- Georgetown University Medical Center
- John R. Wingard, MD
- University of Florida
Shands Cancer Hospital at the University of Florida
Gainesville, Florida
- University of Florida
Board Member Details
Harold J. Burstein, MD, PhD
Professor, Department of Medicine, Harvard Medical School. Boston, Massachusetts
Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.
Bruce D. Cheson, MD
Professor of Medicine, Department of Hematology-Oncology; Deputy Chief, Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC
Bruce D. Cheson, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; AstraZeneca; TG Therapeutics; Celgene; Roche-Genentech; Epizyme; Gilead; Seattle Genetics; Morphosys; Bayer; Karyopharm
Received research grant from: AbbVie; AstraZeneca; TG Therapeutics; Celgene; Roche-Genentech; Epizyme; Gilead; Seattle Genetics; Trillium
David J. Kerr, CBE, MD, DSc, FRCP, FMedSci
Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom
David Kerr, CBE, MD, DSc, FRCP, FMedSci, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celleron Therapeutics; Oxford Cancer Biomarkers; Cancer Care Commission; IQVEA
Received research grant from: Bayer
Have a 5% or greater equity interest in: Celleron Therapeutics; Oxford Cancer Biomarkers; Cancer Care Commission
Received income in an amount equal to or greater than $250 from: Celleron Therapeutics; Oxford Cancer Biomarkers; IQVEA
Mark G. Kris, MD
Professor of Medicine, Weill Cornell Medical College; Attending Physician, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Mark G. Kris, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AstraZeneca; Pfizer; Regeneron
Received honoraria for participating education programs from: WebMD; OncLive; Physicians Education Resource; Prime Oncology; Intellisphere; Creative Educational Concepts; Peerview; i3 Health; Paradigm Medical Communications; AXIS; Carvive Systems; AstraZeneca; Research to Practice
Memorial Sloan Kettering Cancer Center has received funding for research conducted by Dr Kris from: The National Cancer Institute (USA); The Lung Cancer Research Foundation; Genentech Roche; PUMA Biotechnology
Memorial Sloan Kettering Cancer Center has an institutional agreement with IBM for Watson For Oncology and receives royalties from IBM
Funds for business meals, travel, and accommodations have been provided by AstraZeneca and Genentech
Corey J. Langer, MD
Professor of Medicine, University of Pennsylvania Medical School; Director, Thoracic Oncology, Abramson Cancer Center, Philadelphia, Pennsylvania
Corey J. Langer, MD, has disclosed the following relevant financial relationships:
Received institutional grant/research support from: Pfizer; Eli Lilly; Genentech; OSI (Astellas); Merck; GlaxoSmithKline; Nektar; Advantage; Clovis; Inovio; Ariad; StemCentrx; Takeda
Served as a scientific advisor for: AbbVie; Bristol Myers Squibb; ImClone; Pfizer; Eli Lilly; AstraZeneca; Novartis; Roche/Genentech; Bayer/Onyx; Abbott; Morphotek; Biodesix; Clarient; Caris Dx; Vertex; Synta; Celgene; Boehringer-Ingelheim; Hospira; Helsinn; Clovis; Ariad (Takeda); Takai; Regeneron
Data Safety Monitoring Committee Member: Eli Lilly; Amgen; Synta; Agennix; SWOG; Peregrine; Incyte
CME: Projects in Knowledge; Physicians' Education Resource; Network of Oncology Clinicians and Researchers; Imedex; Clinical Care Options; Research to Practice; Med Learning Group; TRM Oncology; WebMD
Maurie Markman, MD
Clinical Professor of Medicine, Drexel University College of Medicine; President, Medicine & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania
Maurie Markman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; Clovis; Tesaro; AstraZeneca Pharmaceuticals, LP
Received income in an amount equal to or greater than $250 from: Merck & Co., Inc.; Nanology; Delmar Pharmaceuticals; Celgene Corporation
John L. Marshall, MD
Professor, Chief, Division of Hematology-Oncology, Department of Oncology, Georgetown University; Director, Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Hospital, Washington, DC
John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck
Serve(d) as a speaker or a member of a speakers bureau for: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck
Received research grant from: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck
Kathy D. Miller, MD
Professor, Department of Hematology/Oncology; Associate Director, Indiana University School of Medicine, Indianapolis, Indiana
Kathy D. Miller, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck & Nektar Breast CA trials (Data and Safety Monitoring Committee)
Richard M. Stone, MD
Professor of Medicine, Harvard Medical School; Director, Translational Research Division, Dana-Farber Cancer Institute, Boston, Massachusetts
Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AbbVie; Actinium; Agios; Amgen Inc.; Arog; Astellas; AstraZeneca; Celgene; Cornerstone; Jazz; Macrogenics; Novartis; Otsuka/Astex; Pfizer; Stemline
Received research funding from: Agios; Arog; Novartis
Serve(d) on the Data Safety and Monitoring Board for: Celgene; Argenx; Takeda
Serve(d) on the Steering Committee for: Celgene
Nicholas J. Vogelzang, MD
Professor of Clinical Medicine, University of Nevada School of Medicine, University of Nevada, Las Vegas, Nevada
Nicholas J. Vogelzang, MD, has disclosed no relevant financial relationships.
Louis M. Weiner, MD
Chairman, Francis L. and Charlotte G. Gragnani Chair and Professor, Department of Oncology, Georgetown University Medical Center; Director, Lombardi Comprehensive Cancer Center; Director, MedStar Georgetown Cancer Institute, Georgetown University Medical Center, Washington, DC
Louis M. Weiner, MD, has disclosed the following relevant financial relationships:
Serve(d) on the Scientific Advisory Board for: Celldex; Jounce Therapeutics; Immunome; Klus Pharmaceuticals; Forty-Seven, Inc.
Serve(d) on the External Advisory Board for: Cytomx
Serve(d) on the Clinical Advisory Board for: Bioxcel
Serve(d) as a consultant for: Novartis
Is the co-founder of: Jounce Therapeutics
Has investment in: Targeted Diagnostic and Therapeutics, Inc.
John R. Wingard, MD
Professor, Department of Medicine, University of Florida; Director, Bone Marrow Transplant Program, Shands Hospital at University of Florida, Gainesville, Florida
John R. Wingard, MD, has disclosed the following relevant financial relationships:
Serve(d) on the board of directors for: National Marrow Transplant Program (Emeritus)
Received income in an amount equal to or greater than $250 from: Shire; Celgene; Astellas; Pluristem; Merck